Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | Ask the Expert: Kevin Kalinsky answers your breast cancer questions at ESMO 2025

Kevin Kalinsky • 20 Oct 2025
ESMO 2025
Breast Cancer

Kevin Kalinsky, MD, MS, Winship Cancer Institute of Emory University, Atlanta, GA, joins us for an “Ask the Expert” session at ESMO 2025, answering global questions from breast cancer professionals, including the best treatment strategies for HR+/HER2- breast cancer, identifying patients who will benefit from endocrine therapy in early-stage HR+ breast cancer, and more. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kevin Kalinsky

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
Emerging molecular biomarkers in breast cancer from the NATALEE trial
0:58
Emerging molecular biomarkers in breast cancer from the NATALEE trial
Kevin Kalinsky • 2 Jun 2025

Related Videos

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
1:15
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
Sanjoy Chatterjee • 17 May 2026
Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
The content of VJOncology is intended for healthcare professionals